1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
2. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(8):819-31.
3. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003;123(6):2096-103.
4. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(8):706-14.
5. Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification. Oncology reports. 2020;43(4):1187-98.
6. Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(12):1576-82.
7. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Archives of pathology & laboratory medicine. 2013;137(9):1191-8.
8. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(7):1109-21.
9. Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL, et al. Tumor recurrence after complete resection for non-small cell lung cancer. The Annals of thoracic surgery. 2012;93(6):1813-20; discussion 20-1.
10. Xi JJ, Yin JC, Wang L, Lu CL, Wang Q, Jiang W. A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer. Journal of thoracic disease. 2018;10(11):6107-17.
11. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(18):2157-64.
12. Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, et al. Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer cytopathology. 2019;127(5):325-39.
13. Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Seminars in cancer biology. 2020;67(Pt 1):74-82.
14. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem cells (Dayton, Ohio). 2009;27(1):40-8.
15. Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, et al. Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PloS one. 2014;9(4):e95303.
16. Ying J, Shi C, Li CS, Hu LP, Zhang WD. Expression and significance of SOX2 in non-small cell lung carcinoma. Oncology letters. 2016;12(5):3195-8.
17. Chou YT, Lee CC, Hsiao SH, Lin SE, Lin SC, Chung CH, et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem cells (Dayton, Ohio). 2013;31(12):2607-19.
18. Iijima Y, Seike M, Noro R, Ibi T, Takeuchi S, Mikami I, et al. Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. International journal of oncology. 2015;46(2):505-12.
19. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012;25(3):405-15.
20. Saghravanian N, Anvari K, Ghazi N, Memar B, Shahsavari M, Aghaee MA. Expression of p63 and CD44 in oral squamous cell carcinoma and correlation with clinicopathological parameters. Archives of oral biology. 2017;82:160-5.
21. Constantinou C, Papadopoulos S, Karyda E, Alexopoulos A, Agnanti N, Batistatou A, et al. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study. In vivo (Athens, Greece). 2018;32(2):303-11.
22. Shibata H, Matsubara O, Wakiyama H, Tanaka S. The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus. Pathology, research and practice. 2001;197(3):157-64.
23. Dai JY, Liang XP, Wen JL, Li CY, Deng CZ, Zhang ZH. [Expression of P27 protein and cyclin E in colon cancer]. Ai zheng = Aizheng = Chinese journal of cancer. 2003;22(10):1093-5.
24. Ribal MJ, Fernandez PL, Lopez-Guillermo A, Farré X, Santos Y, Gibanel R, et al. Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer research. 2003;23(6d):5101-6.
25. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, Delisle MB, Levade T, Uro-Coste E. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer letters. 2002;186(1):115-20.
26. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World journal of gastroenterology. 2005;11(29):4587-91.
27. Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, et al. Deregulated expression of p27(Kip1) in human breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997;3(10):1879-87.
28. Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, et al. Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. Archives of biochemistry and biophysics. 2019;661:97-106.
29. Yang L, Yang J. Expression and clinical significance of microRNA-21, PTEN and p27 in cancer tissues of patients with non-small cell lung cancer. Oncology letters. 2020;20(4):49.
30. Zheng CL, Qiu C, Shen MX, Qu X, Zhang TH, Zhang JH, et al. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2015;16(5):1881-95.
31. Fan J, Zhang W, Lei C, Qiao B, Liu Q, Chen Q, et al. Vascular endothelial growth factor polymorphisms and lung cancer risk. International journal of clinical and experimental medicine. 2015;8(4):6406-11.